About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Letter to the Editor
Efforts are under way to educate health care professionals and the public about deep vein thrombosis, a common, potentially fatal disease.
James Groce III, PharmD, CACP
The authors discuss formulary considerations for the largest therapeutic class of prescription drugs and their efficacy in treating depression and anxiety.
Patrick W. Sullivan, PhD; Robert Valuck, PhD, RPh; Diana I. Brixner, PhD; Edward P. Armstrong, PharmD
Dr. Prescott reviews the latest developments in treatments for malignant and nonmalignant hematological diseases.
Lawrence M. Prescott, PhD
Continuing Education Credit
The authors compare and contrast the safety and efficacy of the newer insulin products—insulin aspart (NovoLog®), lispro (Humalog®), and glargine
(Lantus®)—with existing human insulin (e.g., Humulin®, Novolin®).
Bethany A. Fedutes, PharmD, Amy Calabrese Donihi, PharmD, BCPS, Colleen M. Culley, PharmD, BCPS, Bryan J. McCreery, PharmD Candidate, and Nicole T. Ansani, PharmD
David Nash, MD, MBA, discusses the possibility of limited choices of medications for physicians and the public under the new Medicare drug benefit.
David B. Nash, MD, MBA
Stephen Barlas anticipates the likelihood of decreased Medicaid reimbursement to pharmacies for prescription drugs.
Matthew Grissinger, RPh, FASCP, discusses the risk of errors when staff members are not adequately informed about the potential dangers of glycoprotein IIb/IIIa inhibitors.
Matthew Grissinger, RPh, FASCP
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drs. Hilas and Marzella review ximelagatran (Exanta™), an oral direct thrombin inhibitor.
Olga Hilas, BS, PharmD, and Nino Marzella, BS, PharmD